Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Gilead Sciences and Arcus Biosciences are conducting a Phase 2 study titled A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer. The study aims to assess the safety and efficacy of various immunotherapy combinations in treating PD-L1 positive metastatic non-small cell lung cancer, a significant area of interest due to the high mortality associated with this cancer type.
The study tests three interventions: zimberelimab (AB122) monotherapy, a combination of domvanalimab (AB154) with zimberelimab, and a combination of domvanalimab, zimberelimab, and etrumadenant (AB928). These drugs are designed to enhance the body’s immune response against cancer cells.
This interventional study follows a randomized, parallel assignment model with no masking, focusing on treatment as its primary purpose. It aims to provide insights into the effectiveness of these drug combinations in a real-world setting.
The study began on May 28, 2020, with its primary completion expected by June 25, 2025. These dates are crucial as they guide investors on when to expect potential results and subsequent market impacts.
The update could influence Gilead Sciences and Arcus Biosciences’ stock performance, as positive outcomes may boost investor confidence and competitive positioning in the oncology market. The study’s progress is particularly relevant given the competitive landscape of cancer immunotherapies.
The study is ongoing, and further details are available on the ClinicalTrials portal.